Vizamyl(18F-Flutemetamol[ãã«ãã¡ã¿ã¢ãŒã«]æ³šå ¥å€)ãFDAæ¿èªãããŸãããããã¯ã¢ã«ããã€ããŒç ãèªç¥ç(Alzheimer's disease (AD) and dementia)æ£è ã®è³ã®PETïŒéœé»åæå±€æ®åœ±ïŒã«çšããæ€æ»çšæŸå°æ§è¬å€ã§ãã
èªç¥çã¯è³ã®æ©èœäœäžã«é¢é£ããŠãããèšæ¶åãå€æåãèšèªèœåãè€éãªéåèœå(complex motor skills)ã®äœäžããããããŸããã¢ã«ããã€ããŒç ã«ããçããèªç¥çã¯ãβã¢ããã€ããšåŒã°ããç°åžžãªã¿ã³ãã¯è³ªã®è³å èç©ãããã³è³çŽ°èã®æå·ãŸãã¯æ»æ» ã«é¢é£ããŠããŸããããããβã¢ããã€ãã¯ãç¥çµçŸæ£(neurologic disease)ãåããŠããªãä»ã®èªç¥çã®é«éœ¢æ£è ã®è³å ã§ã確èªã§ããŸãã
Vizamylã¯Î²ã¢ããã€ãã«ä»çããŠã(ããŒã¿ã¢ããã€ãã®ååšã確èªããããã®)è³ã®PETç»åããããããŸãããã¬ãã£ããªVizamylã¹ãã£ã³ã¯ãããŒã¿ã¢ããã€ããã»ãšãã©èç©ããŠããªããããŸãã¯ååšããªãããšãæå³ãããããèªç¥çã®åå ã¯ã¢ã«ããã€ããŒç ã§ã¯ãªãããšã«ãªããŸããããžãã£ããªVizamylã¹ãã£ã³ã¯ãäžçšåºŠã®éãã倧éã®ã¢ããã€ããè³å ã«ããããšãæå³ããŸãããã¢ã«ããã€ããŒç ãä»ã®èªç¥çã確å®ãããã®ã§ã¯ãããŸããããŸããVizamylã¯ã¢ã«ããã€ããŒç ãšèªç¥çã®è©äŸ¡ã§çšããããä»ã®èšºæãã¹ãã代æ¿ãããã®ã§ã¯ãããŸããã
FDAå»è¬åè©äŸ¡ã»ã³ã¿ãŒ(FDAâs Center for Drug Evaluation and Research)ã®è¬å€è©äŸ¡IVéšèª¿æ»å®Shaw Chenã¯æ¬¡ã®ããã«è¿°ã¹ãŠããŸãããèšæ¶ãå€æãªã©ã®ç¥çµæ©èœã®æªååå ãç¹å®ããããã«æ¯å¹Žå€ãã®ã¢ã¡ãªã«äººã蚺å¯ããŠããŸãããä»åŸã¯ã¢ã«ããã€ããŒç ãšèšºæããå¯èœæ§ãé«ãŸãã§ããããVizamylã®ãããªç»å蚺æçšè¬å€ã¯å»åž«ãã¢ã«ããã€ããŒç ããã³èªç¥çã®æ£è ãè©äŸ¡ããäžã§éèŠãªããŒã«ã§ããã
Vizamylã¯ãè³ã®PETã¹ãã£ã³ã§ããŒã¿ã¢ããã€ããå¯èŠåããããã®ç¬¬äºã®èšºæçšè¬ã§ãã2012幎ãFDAã¯ã¢ã«ããã€ããŒãä»ã®èªèäœäžçã®åå ãè©äŸ¡ããããã®è¬å€ãšããŠAmyvid(Florbetapir F 18æ³šå ¥å€)ãæ¿èªããŠããŸãã
Vizamylã®æå¹æ§ã¯ã384åãåå ãã2件ã®èšåºè©Šéšã§ç¢ºèªãããŸããããã¹ãŠã®è¢«éšè ã察象ã«Vizamylã泚å°ããŠã¹ãã£ã³ããŸãããã¹ãã£ã³çµæã®äžéšã¯æ€äœã§ã®ç¢ºèªãè¡ããŸããã
è©Šéšçµæã«ãããVizamyl ã¯è³å βã¢ããã€ããæ£ç¢ºã«æ€åºããããšãããããŸããããŸããã¹ãã£ã³ã¯åçŸå¯èœã§ããããã®èªã¿åããæ£ç¢ºã«è¡ããããšã確èªãããŸããããŸããVizamylã®å®å šæ§ã¯è¢«éšè 761åã§ç¢ºå®ãããŸããã
Vizamylé¢é£ã®å®å šæ§ãªã¹ã¯ã¯ãéæåå¿( hypersensitivity reactions )ã蚺æç»åã®èª€ã£ã解éãæŸå°ç·è¢«ã°ã(radiation exposure)ãªã©ã§ããäž»ãªå¯äœçšã¯é¡é¢çŽ 朮ãé çãè¡å§äžæãåãæ°ãç®ãŸããªã©ã§ãã